Skip to main content
PBLS logo

PBLS · Parabilis Medicines, Inc.

Track PBLS — free
$28.67 +0.42 (+1.49%)
Market Cap
$3.54B
Shares
125.26M
Volume · Nov 18 198.62K Avg daily vol (3M) 944.98K

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$28.25 Open$28.54 Day$27.53–28.54 Available close range$22.75–41.73 Avg vol 30d1.0M Short int11.1M · 8.8% of shares · 8.3d Short vol95% Last earningsNov 12, 2026 DataJun 2026–Nov 2026 Filing10-Q · Nov 12

The closing range uses available history since Jun 10, 2026; less than a full year is stored.

Latest documents

2026
Nov 16
Investor event
Zolucatatide phase 3 set after 72% ORR

Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.

2 source passages
We observed in that tumor type a 72% ORR at 32 weeks. We have met with the FDA at an end of phase 2 meeting and have a clear green light to proceed with phase 3 that we call the pedestal study, and that's slated to start in the first half of next year Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Net loss widens to $44.5 million in third quarter

Net loss widened to $44.5 million for the three months ended September 30, 2026, from $33.5 million a year earlier. Research and development expense rose to $45.6 million, mainly from higher external costs for zolucatetide. Cash, cash equivalents and marketable securities totaled $1,072.9 million at September 30, 2026, which the company expects to fund operations into 2030.

Revenue $2.11M Net loss $44.49M Diluted EPS -$0.36
Read from the MD&A section
5 source passages
Our net losses were $44.5 million and $33.5 million for the three months ended September 30, 2026 and 2025, respectively. Research and development expense was $45.6 million for the three months ended September 30, 2026, as compared to $28.2 million for the three months ended September 30, 2025. an increase in external expenses for our lead product candidate, zolucatetide, of $9.7 million, which was primarily attributable to increases in costs incurred for CROs, CMOs and consultants As of September 30, 2026, we had total cash, cash equivalents and marketable securities of $1,072.9 million. We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into 2030. Open the document at this passage
Nov 12
Current report 8-K
Zolucatetide 72.2% response in evaluable ≥450 mg patients

Parabilis Medicines reported a 72.2% objective response rate at the 32-week landmark among evaluable desmoid-tumor patients receiving a starting dose of ≥450 mg; $1.1 billion in cash, cash equivalents and marketable securities is expected to fund operations into 2030.

Financial results
2 source passages
An objective response rate (ORR) of 72.2% (13/18) among patients evaluable at the 32-week landmark who received a starting dose of ≥450 mg Ended the third quarter with $1.1 billion in cash, cash equivalents and marketable securities, expected to fund operations into 2030 Open the document at this passage
Nov 9
Investor event
Zolucatetide advances toward global Phase Three after strong desmoid results

Parabolus plans to initiate the global pedestal Phase Three study of Zolucatetide in the first half next year, following an FDA-agreed induction-maintenance regimen; desmoid data showed 62% ORR at 24 months and 72% ORR at 32 weeks.

4 source passages
So for investors who are getting still to know the Parabolus story, what is the core idea behind the Helicon platform and what does it enable you to do? And so we're very proud of that going into the phase three study that we're calling pedestal. And we're still committed to initiating that study in the first half next year. One is that we have agreed a dose and schedule regimen with FDA. So we were able to report at 24 months a 62% ORR, and at 32 weeks, we were able to see a 72% ORR. Open the document at this passage
Nov 5
Current report 8-K Events of Oct 30
Headquarters expansion begins January 1, 2028

Parabilis Medicines, Inc. amended its headquarters lease to add 33,525 square feet beginning January 1, 2028, extend the term through December 31, 2037, and provide an option for two additional five-year periods.

Entered into a material agreement
4 source passages
On October 30, 2026, Parabilis Medicines, Inc. (the “Company”) and LS 400/500 CDP, LLC (the “Landlord”) entered into a Third Amendment of Lease (the “Amendment”), which amends certain provisions of that certain Lease Agreement, by and between the Company and 400 Discovery Park, LLC, dated as of April 22, 2019, as amended (the “Lease”), regarding the Company’s corporate headquarters located at 30 Acorn Park Drive, Cambridge, Massachusetts (the “Existing Property”). The Amendment provides for, among other things: (i) an expansion, beginning on January 1, 2028, of the leased space by a total of 33,525 square feet on the first and sixth floors of the annexed building at 20 Acorn Park Drive (the “Neighboring Property” and, together with the Existing Property, the "Premises") with rent commencing on January 1, 2029, (ii) an amendment to the Company’s existing right of first offer, subject to certain conditions, to lease certain other space at the Neighboring Property as and when such space becomes available, and (iii) options, subject to certain conditions, to expand the Lease to cover certain additional space at the Premises. Pursuant to the Amendment, the term of the Lease is extended for an additional period, commencing on March 1, 2031 and expiring on December 31, 2037 (the “Extension Term”). The Amendment provides that the Company will have an option to further extend the term of the Lease for two additional five-year periods from the end of the Extension Term, subject to certain conditions. Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$1.11B
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+6,002.5%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
8.8%
Latest settlement · 8.3 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Neutral Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 25.5 · fear Equity put/call 0.71
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 50-day avg −7%
below
RSI (14) 48
neutral
MACD trend Positive
52-week position 29%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+62% holders QoQ · +58 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.82% of shares out · ▲ +19.5% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
128 holders — 13F breadth
Squeeze score 72
high risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 74%
annualized · 1-yr
Max drawdown −45%
past year
ATR 7.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
1 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−7% Bearish
RSI (14)
48 Neutral
MACD trend
Positive Bullish
52-week position
29% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+62% holders QoQ · +58 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
8.82% of shares out · ▲ +19.5% MoM · 8.3 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
128 holders — 13F breadth
Price context
position in its available closing range
Range low $23 Now $28 · 29% Range high $42
vs 50-day avg -7%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
disease control rate (DCR) 100% June 22, 2026 data cut —
objective response rate (ORR) 72.2% June 22, 2026 data cut —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PBLS
Parabilis Medicines, Inc.
this stock
$3.54B — — — 8.8%
VRTX
Vertex Pharmaceuticals Inc
$135.44B +17.8% +46.2% 34.4 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$99.08B +24.1% +20.8% 21.2 2.1%
MRNA
Moderna, Inc.
$83.68B +601.3% +4.3% — 8.2%
CSLLY
Csl Ltd
$64.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
128
% held
87.9%
Net QoQ
+11.1M sh
Top holder
RA CAPITAL MANAGEMENT, L.…
Held Float
View
Held by Funds
Fund positions
42
View
Short & Settlement
Short Interest Rising
Shares short
11.1M
Days to cover
8.3d
Change
+1.8M sh
View
Short Volume
Short vol %
95%
As of
Nov 17, 2026
Short Total
View
Fails to Deliver
FTD shares
88.7K
Value
$2.5M
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
49.5%
Week of
Oct 12, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Nov 16, 2026
This year
16

Parabilis Medicines, Inc. plans to begin a phase 3 study of zolucatatide in the first half of next year after an FDA end-of-phase 2 meeting cleared the path, following a 72% ORR at 32 weeks in desmoid tumors.

View
Exempt Offerings
Offering
$178.0M
Filed
Dec 2, 2022
View
Earnings & Events
Webcasts Upcoming
Next webcast
Nov 30, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
Parabilis Medicines Reports Third…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PBLS -5.9% +4.3% — -0.3% —
SPY -2.3% -4.8% -2.9% -3.1% +7.4%
vs SPY -3.6% +9.1% — +2.8% —
Key facts CIK 1657677 CUSIP 698955101 13F (30d) 124 filings 124 filers Visit website Investor relations